Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

Clinical Pharmacology and Therapeutics
Kenta YoshidaShiew-Mei Huang

Abstract

Recent reviews suggest that chronic kidney disease (CKD) can affect the pharmacokinetics of nonrenally eliminated drugs, but the impact of CKD on individual elimination pathways has not been systematically evaluated. In this study, we developed a comprehensive dataset of the effect of CKD on the pharmacokinetics of CYP2D6- and CYP3A4/5-metabolized drugs. Drugs for evaluation were selected based on clinical drug-drug interaction (CYP3A4/5 and CYP2D6) and pharmacogenetic (CYP2D6) studies. Information from dedicated CKD studies was available for 13 and 18 of the CYP2D6 and CYP3A4/5 model drugs, respectively. Analysis of these data suggests that CYP2D6-mediated clearance is generally decreased in parallel with the severity of CKD. There was no apparent relationship between the severity of CKD and CYP3A4/5-mediated clearance. The observed elimination-route dependency in CKD effects between CYP2D6 and CYP3A4/5may inform the need to conduct clinical CKD studies with nonrenally eliminated drugs for optimal use of drugs in patients with CKD. This article is protected by copyright. All rights reserved.

References

Jun 1, 1991·Journal of Clinical Pharmacology·V D SchmithP D Kroboth
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·G D DoyleB D Zussman
Feb 1, 1989·Journal of Clinical Pharmacology·E BurgessP Wilkes
Jul 1, 1986·Clinical Pharmacology and Therapeutics·R H BergstrandA J Wood
Jan 1, 1987·Anesthesia and Analgesia·M ChauvinP Duvaldestin
May 1, 1988·Kidney International·R VanholderS Ringoir
Oct 1, 1986·Journal of Clinical Psychopharmacology·H R OchsR B Smith
Oct 1, 1980·Journal of Pharmacokinetics and Biopharmaceutics·L BalantJ Fabre
Jul 1, 1984·Clinical Pharmacology and Therapeutics·G R AronoffL Lemberger
Nov 1, 1983·Anesthesiology·H R VinikL R Smith
Jul 1, 1981·British Journal of Clinical Pharmacology·S DawlilngR Braithwaite
Jul 1, 1994·Clinical Pharmacology and Therapeutics·S M TroyR A Blum
May 25, 2005·Clinical Pharmacokinetics·Arthur J BergmanAnup Majumdar
Oct 15, 2005·Nature Reviews. Drug Discovery·Larry C Wienkers, Timothy G Heath
Nov 18, 2005·Journal of Clinical Pharmacology·Paula Macedo CerqueiraVera Lucia Lanchote
Aug 11, 2006·Journal of the American Society of Nephrology : JASN·Thomas D NolinJonathan Himmelfarb
Apr 5, 2008·Clinical Pharmacology and Therapeutics·T D NolinV Pichette
Jul 31, 2009·Clinical Pharmacology and Therapeutics·D E Weiner
Aug 22, 2009·Journal of the American Society of Nephrology : JASN·Thomas D NolinJonathan Himmelfarb
Sep 25, 2009·Clinical Pharmacology and Therapeutics·R L Lalonde, J A Wagner
Dec 29, 2010·Investigational New Drugs·John W BaumanMaria Gutierrez
Oct 1, 2011·Journal of Clinical Pharmacology·Kathleen Butler, Renli Teng
Nov 26, 2011·Expert Review of Clinical Pharmacology·Karen Rowland YeoAmin Rostami-Hodjegan
Mar 5, 2013·Clinical Pharmacokinetics·Michael J RoyJames J Keirns
May 15, 2013·Biochimica Et Biophysica Acta·Keishi YamasakiMasaki Otagiri
Oct 15, 2013·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Masayuki TsujimotoKohshi Nishiguchi
Oct 18, 2013·Kidney International·Catherine K YeungJonathan Himmelfarb
Jul 26, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Akihiro HisakaHiroshi Suzuki
Jun 26, 2015·Journal of Clinical Pharmacology·Pravin R JadhavJ Robert Powell
Oct 1, 2013·Clinical Pharmacology in Drug Development·David J Greenblatt

❮ Previous
Next ❯

Citations

Apr 10, 2017·Journal of Pharmaceutical Sciences·Aleksandra GaletinShiew-Mei Huang
Sep 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Federico Pea
Jul 31, 2018·Clinical Pharmacology and Therapeutics·Yingying GuoUNKNOWN International Transporter Consortium
Jul 30, 2019·Journal of Clinical Pharmacology·Estela Hanauer SchaabEduardo Barbosa Coelho
Jun 24, 2018·Clinical Journal of the American Society of Nephrology : CJASN·Tom N Lea-HenryDarren M Roberts
Aug 4, 2019·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Anne M SchijvensMichiel F Schreuder
May 7, 2020·Archives of Toxicology·Si ChenLei Guo
Oct 13, 2017·Clinical Pharmacology and Therapeutics·Amin Rostami-Hodjegan
Nov 8, 2019·Clinical Pharmacology in Drug Development·Anne N NafzigerMichael J Fossler
Jul 2, 2017·Clinical Pharmacokinetics·Elisa BorellaPaolo Magni
May 2, 2020·Clinical Pharmacology and Therapeutics·Erlend Johannessen EgelandIda Robertsen
Sep 1, 2018·European Journal of Drug Metabolism and Pharmacokinetics·Roberto Padrini
Oct 11, 2020·Cancer Chemotherapy and Pharmacology·Yanke YuDiane Wang
Jul 25, 2020·Clinical Pharmacology and Therapeutics·Daniel A TatosianS Aubrey Stoch
Dec 24, 2019·Acta Pharmaceutica Sinica. B·Yuhua LiHuichang Bi
Nov 19, 2020·Journal of Clinical Pharmacology·Yoko Franchetti, Thomas D Nolin
Nov 19, 2020·Journal of Clinical Pharmacology·Paul R V MalikAndrea N Edginton
Oct 21, 2020·Expert Opinion on Drug Metabolism & Toxicology·Dorsa MaherEmily Reeve
Jul 18, 2021·Journal of Clinical Pharmacology·Kenta YoshidaPascal Chanu

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

GastroPlus

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.